



**MEDICARE ENROLLMENT & APPEALS GROUP**

**DATE:** August 20, 2020

**TO:** All Organizations Offering Part D

**FROM:** Jerry Mulcahy  
Director, Medicare Enrollment & Appeals Group

**SUBJECT:** Revised Part D Notice of Denial of Medicare Prescription Drug Coverage  
(CMS 10146)

The purpose of this memorandum is to announce the availability of the revised, OMB-approved standardized Notice of Denial of Medicare Prescription Drug Coverage (CMS-10146). The notice and instructions are posted under “Downloads” at:

<http://www.cms.gov/Medicare/Appeals-and-Grievances/MedPrescriptDrugApplGriev/PlanNoticesAndDocuments.html>

The revised OMB-approved standardized Notice of Denial of Medicare Prescription Drug Coverage (CMS-10146) is available now for implementation, but CMS will not enforce use of the notice until **January 1, 2021**. The revised Part D standardized denial notice must be provided to Part D enrollees when a Part D plan sponsor issues a fully or partially adverse coverage determination.

The revised version of the Part D standardized denial notice has been modified to include instructions for Part B step therapy, as applicable for MA-PD plans. Specifically, if the plan determines that the requested drug is typically covered under Part B and processes the request as a Part C organization determination, the plan must send the Integrated Denial Notice (CMS-10003) if coverage is denied under Part B (e.g., Part B drug step therapy requirements have not been met).

**Questions**

For questions regarding the denial notice, submit to the Part D Appeals and Grievances resource portal: <https://appeals.lmi.org> .